Chattem (CHTT) Reports Q3 Adj-EPS of $1.31, Beats by 10c; Reaffirms FY09 Outlook
More News related to CHTT
- LecTec Corporation and Endo Pharmaceuticals Inc. Settle Patent Dispute
- Chattem (CHTT) Reports Q3 Adj-EPS of $1.31, Beats by 10c; Reaffirms FY09 Outlook
- Chattem Reports Increased Revenues and Earnings; Affirms Fiscal 2009 Guidance
- Trading Radar for 10/06: Yum! (YUM), Pepsi Bottling (PBG), Chattem (CHTT), AngioDynamics (ANGO) Report
- Morgan Stanley Initiates Coverage on Chattem (CHTT) with an Equalweight Rating
More News related to Earnings
- Prudential Bancorp of Penn. (PBIP) Swings to Q4 Profit
- Pharmasset (VRUS) Reports Inline Q4 Loss of $0.53
- Sterling Banks (STBK) Swings to Q3 Loss
- Highlights From DE's Q4 Conference Call: Production Will Pick Up in 2010, But Overall Conditions to Remain Fairly Restrained
- Highlights From TIF's Q3 Conference Call: Sales Declines, But Less-Than-Expected; Raises FY Outlook
Chattem Inc. (Nasdaq: CHTT) reports Q3 EPS of $1.31, 10 cents better than the analyst estimate of $1.21. Revenue for the quarter was $115.2 million, which compares to the estimate of $116.70 million.
Reaffirms its FY09 outlook.
Related Categories
EarningsGuidance
Stocks Mentioned
-0.61Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
